The efficacy of Zafirlukast as a SARS-CoV-2 helicase inhibitor in adult patients with moderate COVID-19 Pneumonia (pilot randomized clinical trial)

OBJECTIVE: To assess the efficacy of Zafirlukast as a SARS-CoV-2 Helicase Inhibitor in adult patients with moderate COVID-19 symptoms (hospitalized patients with COVID-19 pneumonia who were not admitted to an intensive care unit). METHODS: We conducted a randomized, double blind, placebo-controlled,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghobain, M.Al, Rebh, F., Saad, A., Khan, A.H., Mehyar, N., Mashhour, A., Islam, I., Alobaida, Y., Alaskar, A.S., Boudjelal, M., Jeraisy, M.Al
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673052/
https://www.ncbi.nlm.nih.gov/pubmed/36436481
http://dx.doi.org/10.1016/j.jiph.2022.11.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673052/
https://www.ncbi.nlm.nih.gov/pubmed/36436481
http://dx.doi.org/10.1016/j.jiph.2022.11.016

Ejemplares similares